Compare KLA Corp. (KLAC) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Oscar Health Inc — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: KLA Corp. is far larger — about 25.1× Oscar Health Inc's market cap, and KLA Corp. pays a 0.47% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Oscar Health Inc for 15 Days on average.
| KLAC | OSCR | |
|---|---|---|
Market Cap | $256.72B | $10.22B |
Volume | 9,970,753 | 4,123,394 |
Sector | Technology | Health |
52-Week High | $301.71 | $33.81 |
52-Week Low | $98.28 | $10.85 |
Typical Hold Time | 60 Days | 15 Days |
Enterprise Value | $257.97B | $6.57B |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $196.72, showing slight daily weakness but maintaining a strong uptrend supported by bullish technical indicators and robust fundamentals. The company reported revenue of $12.16 billion in 2025 with a net income margin of 35.57%, and has consistently beaten earnings expectations in recent quarters. AI-driven demand is fueling growth, with a backlog of $12.57 billion highlighting strong future revenue visibility.
The outlook for KLAC remains positive, driven by semiconductor equipment demand from AI and advanced packaging. Key opportunities include market leadership in inspection and metrology, while risks involve competitive pressures from Applied Materials and ASML, and execution challenges in scaling operations. The consensus price target of $223.88 suggests significant upside potential from current levels.
OSCR trades at $33.37, up 1.4% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent Q1 and Q2 2026 earnings beat expectations, while analyst consensus leans toward Hold (61.54%) with a $34 price target. Technical indicators show bullish signals but RSI suggests potential overbought conditions near-term.
Outlook remains positive with scalable ACA market growth and margin expansion driving earnings potential. Key risks include rising medical costs threatening profitability and competitive pressures. The stock offers growth exposure but requires monitoring of execution on 2029 EPS targets of $4+ and medical loss ratio management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
